Bedrijfsoverzicht
Viridian Therapeutics, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing treatments specifically designed for serious and rare diseases. The company focuses its research and development efforts on creating IGF-1R therapies, with a particular emphasis on addressing thyroid eye disease through the administration of Veligrotrug, a differentiated humanized monoclonal antibody. Operating within the healthcare sector as a biotechnology industry participant, the company leverages its specialized expertise to target niche medical conditions that often lack effective standard therapies. With a market capitalization of $1.53 billion, annual revenue of $70.85 million, and an employee base of 252, the organization maintains a substantial asset position relative to its operational footprint. These valuation metrics indicate that the market assigns a premium to the company's intellectual property pipeline and its strategic focus on unmet medical needs, suggesting significant potential value embedded in its R&D portfolio despite the current lack of profitability.
Financiële gezondheid
The company reported a revenue of $70.85 million over the trailing twelve months, yet it recorded a net income of -$281,928,000 and an EBITDA of -$362,935,008, revealing a cost structure where operating expenses significantly outweigh generated income. This substantial gap between revenue and net income highlights the heavy investment required in clinical trials, regulatory submissions, and manufacturing scale-up typical of the biotechnology sector. Free cash flow stands at -$162,068,368, indicating that the company is burning through capital to fund its growth initiatives rather than generating surplus liquidity for immediate distribution. The gross margin is recorded at 0.0%, while the operating margin is -95643.2% and the profit margin is 0.0%, figures that collectively reflect the early-stage nature of the business where costs are disproportionately high before product commercialization scales. Despite the negative earnings, the balance sheet shows a robust cash position of $874.65M against total debt of $52.59M, resulting in a debt-to-equity ratio of 7.28 which suggests a leveraged structure but one heavily cushioned by cash reserves. The current ratio of 12.65 demonstrates exceptional short-term liquidity, providing ample coverage for current liabilities and operational obligations. Furthermore, the return on equity is -49.2% and the return on assets is -27.7%, metrics that reveal management is currently deploying capital to generate future returns rather than delivering immediate shareholder yield, a common characteristic for companies in the development phase.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to the absence of net income, while the forward P/E is listed at -6.66, a negative figure implying that the market expects earnings to remain negative or that valuation models are adjusting for the lack of current profitability. The price-to-book ratio stands at 2.58, indicating that the stock trades at a premium of 158% over its book value, which reflects investor confidence in the company's intangible assets and future commercial potential. Alternative valuation metrics such as the price-to-sales ratio of 21.57 and an EV/EBITDA of -2.31 suggest that the company is valued based on its revenue generation capabilities and future growth prospects rather than current earnings power. The stock has traded between a 52-week high of $34.29 and a 52-week low of $11.76, and without a specific current share price provided in the data, the valuation context relies on the proximity of the trading range to these extremes to gauge recent market sentiment. The beta of 1.17 indicates that the stock's price volatility is 17% higher than the broader market, suggesting that price movements will likely be more pronounced during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year has accelerated to 83.3%, demonstrating strong top-line expansion, whereas earnings growth is N/A due to the company's continued losses, implying that revenue is growing faster than earnings as the business scales toward profitability. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings are theoretically retained, though currently negative, and that the firm prioritizes reinvesting resources into research and development rather than distributing income to shareholders. The absence of a dividend policy aligns with the company's lifecycle stage, where capital retention is essential for advancing clinical programs and securing regulatory approvals for its therapies. Overall, the growth and income profile is characterized by aggressive revenue expansion funded by significant cash reserves, with no current income distribution, positioning the firm for long-term potential rather than short-term yield.